Abstract
Paraoxonase 1 (PON1) is an enzyme which is mainly synthesized in the liver. PON1 circulates in the blood bound to HDL and delays or prevents the oxidation of LDL. Single nucleotide polymorphisms significantly determine PON1 status in humans. A high PON1 status may be associated with a reduced cardiovascular disease risk. By using in silico databases we suggest various transcription factors and micro RNA as putative regulators of PON1. Furthermore we predict functional partners of PON1 by using a text mining tool. Beside genetic and life style factors PON1 status may be determined by drugs (e.g., statins, fibrates) and dietary factors. Dietary modulators of PON1 status include fat and fatty acids, antioxidant vitamins (e.g. ascorbic acid, tocopherol), polyphenols and polyphenol-rich foods.
Keywords: Aging, antioxidant, cardiovascular disease, diet, drugs, fibrate, flavonoids, genetic regulation, oxidized LDL, paraoxonase, polymorphism, polyphenols, statin
Current Medicinal Chemistry
Title: Determinants of Paraoxonase 1 Status: Genes, Drugs and Nutrition
Volume: 18 Issue: 36
Author(s): C. Schrader and G. Rimbach
Affiliation:
Keywords: Aging, antioxidant, cardiovascular disease, diet, drugs, fibrate, flavonoids, genetic regulation, oxidized LDL, paraoxonase, polymorphism, polyphenols, statin
Abstract: Paraoxonase 1 (PON1) is an enzyme which is mainly synthesized in the liver. PON1 circulates in the blood bound to HDL and delays or prevents the oxidation of LDL. Single nucleotide polymorphisms significantly determine PON1 status in humans. A high PON1 status may be associated with a reduced cardiovascular disease risk. By using in silico databases we suggest various transcription factors and micro RNA as putative regulators of PON1. Furthermore we predict functional partners of PON1 by using a text mining tool. Beside genetic and life style factors PON1 status may be determined by drugs (e.g., statins, fibrates) and dietary factors. Dietary modulators of PON1 status include fat and fatty acids, antioxidant vitamins (e.g. ascorbic acid, tocopherol), polyphenols and polyphenol-rich foods.
Export Options
About this article
Cite this article as:
Schrader C. and Rimbach G., Determinants of Paraoxonase 1 Status: Genes, Drugs and Nutrition, Current Medicinal Chemistry 2011; 18 (36) . https://dx.doi.org/10.2174/092986711798347216
DOI https://dx.doi.org/10.2174/092986711798347216 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Newer Insights in Personalized and Evidence Based Medicine- the Role of MicroRNAs
Current Pharmacogenomics and Personalized Medicine The Role of Coronary Angioplasty in the Management of Patients with Stable Coronary Artery Disease
Cardiovascular & Hematological Disorders-Drug Targets Vitamin D in COPD - A Pleiotropic Micronutrient in a Multisystem Disease
Current Respiratory Medicine Reviews Early Functional and Structural Microvascular Changes in Hypertension Related to Aging
Current Hypertension Reviews Anticancer Drug Discovery Targeting DNA Hypermethylation
Current Medicinal Chemistry Angiogenesis Inhibitors: Current & Future Directions
Current Pharmaceutical Design Primary Prevention of Ischaemic Stroke in Atrial Fibrillation: New Oral Anticoagulant Drugs for all?
Current Vascular Pharmacology Novel Agents Targeting Nitric Oxide
Current Vascular Pharmacology The Role of Chemokines, Cytokines and Adhesion Molecules in Stem Cell Trafficking and Homing
Current Pharmaceutical Design Using Properties of Tumor Microenvironments for Controlling Local, On-Demand Delivery from Biopolymer-Based Nanocarriers
Current Pharmaceutical Design Vascular Endothelin and Hypertension - From Receptors to Medicine
Current Hypertension Reviews Reactive Oxygen Species and Antioxidants in the Pathophysiology of Cardiovascular Disease: Does the Actual Knowledge Justify a Clinical Approach?
Current Vascular Pharmacology Stressing Conditions as Tools to Boost the Biosynthesis of Valuable Plant Natural Products
Recent Patents on Biotechnology Treating Hypertension in the Elderly: Common Problems and Solutions
Current Hypertension Reviews Conventional and Non-Conventional Targets of Natural Products in the Management of Diabetes Mellitus and Associated Complications
Current Medicinal Chemistry Innate Immunity and the Heart
Current Pharmaceutical Design Linc01638 Promotes Tumorigenesis in HER2+ Breast Cancer
Current Cancer Drug Targets Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Inflammation in Coronary Artery Disease and Acute Myocardial Infarction - is the Stage Set for Novel Therapies?
Current Pharmaceutical Design Inflammation in Peripheral Arterial Disease (PAD)
Current Pharmaceutical Design